Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanostart-held Curiox Biosystems wins Emerging Company award

Abstract:
* "Emerging Company of the Year in Asia Pacific" in biomedical sciences
* "Curiox is a potential industry leader within 10 years"
* Expanding in USA, Europe and Japan

Nanostart-held Curiox Biosystems wins Emerging Company award

Singapore / Frankfurt | Posted on March 16th, 2010

Curiox was awarded "Emerging Company of the Year 2010 in Asia Pacific", on 12th March, by BioSpectrum Asia. BioSpectrum Asia is a leading B2B media platform covering the life sciences industry in the Asia Pacific region.

Curiox and other Asia Pacific companies were assessed on the basis of their achievements and potential for future growth to determine companies that shall emerge as industry leaders, in the biomedical science and biotechnology sectors, in the coming decade. BioSpectrum's team of industry experts evaluated all aspects of the organizations' performance and public profile, prior to nominating Curiox as the winner of the award in the sector biomedical sciences. The award was given to five more companies from other sectors in life sciences and medical technologies.

Curiox's "Emerging Company of the Year" award comes hot on the heels of Curiox's LabAutomation2010 "Innovation AveNEW" award, earlier this year; as one of the industry's most innovative laboratory automation technology. This magnitude of worldwide industry acceptance and excitement for is welcomed by the young Singaporean start-up Curiox; and comes at a crucial time as Curiox begins to expand its products to overseas markets.

"It is truly an honour to be selected with top companies in Asia who have been around much longer than Curiox. These awards demonstrate to our customers, partners and competitors that our DropArray™ technology is truly innovative, and is recognized by industry experts (on a global scale) to be beneficial and potentially disruptive to the laboratory automation industry," comments Curiox's CEO Dr Namyong Kim.

Curiox's patent-pending DropArray™ technology provides a next-generation "wall-less" microtiter platform, and complimentary washing instrument, to provide researchers with better quality of data, 10 - 50 times savings in sample and reagent consumption, and up to 60 % assay time reduction. Additionally, DropArray™ technology promotes integration with liquid handling systems by maintainaining reproducibility and compatibility with existing microtiter plate detection systems.

Curiox Biosystems intends to penetrate the United States, European and Japanese laboratory markets this year through strategic partnerships and distributors.

According to BioSpectrum Asia, it has a readership of over 150,000 (including print magazine, online-edition and website) of which a large majority represent key decision makers in the Pharma and Biotech industry.

The Nanostart Singapore Early Stage Venture Fund I holds almost 19% in Curiox Biosystems.

Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the "Entry Standard" segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.

####

About Nanostart AG
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.

About Curiox Biosystems Pte Ltd
Curiox Biosystems has a vision to accelerate the progress of life sciences and drug discovery through better miniaturization. Curiox is a bioinstrumentation company enabling the miniaturization of heterogeneous bioassay for researchers working in life sciences, drug discovery, and diagnostics. Curiox’s patented miniaturization platform, DropArray™, provides up to 1,000 times savings in sample and reagent consumption, and up to 10 times reduction in assay time. The company is located in Singapore, the biomedical hub of Southeast Asia. The company is a spin-off from Institute of Bioengineering and Nanotechnology (IBN) backed primarily by Nanostart and Exploit Technologies, the commercializing arm of Singapore’s Agency for Science, Technology and Research (A*STAR). For further information, please visit www.curiox.com.

For more information, please click here

Contacts:
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail:

Copyright © Nanostart AG

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Shape matters when light meets atom: Mapping the interaction of a single atom with a single photon may inform design of quantum devices December 4th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Investments/IPO's/Splits

Harris & Harris Group Issues Letter to Shareholders and Information for Shareholder Call on Tuesday, November 15, 2016 November 14th, 2016

Harris & Harris Group Issues Business Update and Reports Financial Statements as of September 30, 2016 November 9th, 2016

Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016

Harris & Harris Group Notes Announcements by Its Portfolio Companies During the Third Quarter of 2016 September 30th, 2016

Announcements

Shape matters when light meets atom: Mapping the interaction of a single atom with a single photon may inform design of quantum devices December 4th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Tools

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Controlled electron pulses November 30th, 2016

Scientists shrink electron gun to matchbox size: Terahertz technology has the potential to enable new applications November 25th, 2016

News from Quorum: The Agricultural Research Service of the USDA uses a Quorum Cryo-SEM preparation system for the study of mites, ticks and other soft bodied organisms November 22nd, 2016

Nanobiotechnology

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

Making spintronic neurons sing in unison November 18th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project